U.S., Nov. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07252791) titled 'Safety and Immunogenicity of PCV20 in Pediatric Patients With Autoimmune Rheumatic Diseases' on Aug. 20.
Brief Summary: This clinical trial evaluates the immunogenicity (humoral and cellular) and safety of the 20-valent pneumococcal conjugate vaccine (PCV20) in children, adolescents, and young adults aged 2-25 years with autoimmune rheumatic diseases (ARDs). All participants will receive PCV20 according to prior vaccine history. Antibody titers, opsonophagocytic activity, cellular immune responses, and adverse events will be measured up to 6 months post-vaccination. Effects of immunosuppressive therapy and physical activity levels r...